

American Journal of
**Drug Discovery
and Development**

ISSN 2150-427X



Academic
Journals Inc.

www.academicjournals.com

***In vitro* Antioxidant Activity of Itrifal Kishneezi: A Unani Formulation**

¹A. Koneru, ²S. Satyanarayana, ³K. Mukkanti and ¹K.A. Khan

¹Department of Pharmacology, Sultan-ul-Uloom College of Pharmacy, Hyderabad, India

²Avanthi Institute of Pharmaceutical Sciences, Vizianagaram, Andhra Pradesh, India

³Pharmaceutical Sciences, Jawaharlal Nehru Technological University, Hyderabad, India

Corresponding Author: Anupama Koneru, Sultan-ul-Uloom College of Pharmacy, Road No. 3 Banjara Hills, Hyderabad-500 034, India Tel: 91-98666 55547

ABSTRACT

Unani system of medicine (Unanipathy) originated in Greece, enriched by Persians and Arabs and now became an integral part of Alternative medicinal systems of India. Itrifal Kishneezi is a Unani medicine prescribed for gastric problems, head ache and used as a stimulant. The present study was taken up as there is no published scientific data available. The drug was tested for antioxidant activity, as there is growing evidence of role of free radicals in disease progression in number of diseases and benefits of concomitant antioxidant administration. Itrifal Kishneezi was tested for DPPH[•] free radical scavenging and Fe²⁺ metal ion chelating activity using UV-Vis spectrophotometer. It showed considerable *in vitro* antioxidant activity in a dose dependent manner.

Key words: Unani, Itrifal Kishneezi, DPPH[•], ferrozine, free radicals, antioxidant

INTRODUCTION

Unani system of medicine (Unanipathy) originated in Greece based on the principles propounded by Galen, a Greek Practitioner and was called Galenic. After him many Arab and Persian scholars enriched the system and became Unani (Ahmad and Akhtar, 2009). Now it has become a part of Indian traditional system of medicine (Anupama *et al.*, 2009).

Itrifal Kishneezi (IK) is used in unani for chronic catarrh, gastric problems-flatulence, indigestion, hyperacidity; head ache, eye pain and as a stimulant (Gupta, 2003; Kabeeruddin, 1989; Rehman, 1985). IK contains Terminalia chebula (Myrobalan)-black Myrobalan (unripe fruit-0.435 g), yellow myrobalan (fresh ripe fruit-0.435 g) and brown myrobalan (dried ripe fruits-0.435 g); Terminalia belerica (0.435 g); Coriandrum sativum (0.435 g); clarified butter (ghee-0.866 g) and honey (6.953 g).

Terminalia chebula is shown to have antibacterial, antifungal (Inamdar *et al.*, 1959), purgative (Miglani *et al.*, 1971), hypolipidemic (Khanna *et al.*, 1993), anthelmintic (Dwivedi *et al.*, 2008) and anticancer activities (Kaur *et al.*, 1998; Saleem *et al.*, 2002). It is used for flatulence, constipation, diarrhoea, dysentery, cyst, digestive disorders, vomiting, enlarged liver and spleen, cough and bronchial asthma, metabolic harmony; as diuretic and antioxidant (Kokate *et al.*, 2002; Evans, 2006; Khare, 2007; Chattopadhyay and Bhattacharyya, 2007). Terminalia belerica has

purgative, astringent, antipyretic, hypotensive actions and is also used in diarrhoea, dyspepsia, biliousness, cough, bronchitis, upper respiratory tract infections, tropical pulmonary eosinophilia, helminthiasis and allergic eruptions (Kokate *et al.*, 2002; Evans, 2006; Khare, 2007). It is shown to have hepatoprotective (Anand *et al.*, 1997; Jadon *et al.*, 2007), antidiabetic, antioxidant (Sabu and Kuttan, 2009) and antisalmonella (Madani and Jain, 2008) activities. *Coriandrum sativum* is used as stimulant, stomachic, carminative, anti-spasmodic, diuretic, hypoglycemic, anti-inflammatory, bactericidal, larvicidal and in measles, aerophagy, gastroenteritis, bleeding piles, neuralgia, cephalalgia, spermatorrhoea and viral infections (Kokate *et al.*, 2002; Evans, 2006; Khare, 2007). It is shown to have antidiabetic (Swanston-Flatt *et al.*, 1990; Gray and Flatt, 1999), antifertility (Al-Said *et al.*, 1987), hypolipidemic (Chithra and Leelamma, 1997), antioxidant (Chithra and Leelamma, 1999) and hypotensive (Medhin *et al.*, 1986) activities. Clarified butter increases intelligence, enhances memory, enhances bioavailability and is an appetizer. It is an antioxidant and is also useful in psychological disorders and epilepsy (Shastri, 1998). Honey is useful in cough, sore throat, acidity, diabetic ulcers, colitis, inflammation (Bilsel *et al.*, 2002; Al-Waili, 2004), wound healing (Molan, 2006) and as a sweetener (Shastri, 1998).

Studies showed the significance of oxidative stress, mitochondrial dysfunction and free radicals in aging and in the pathogenesis of many diseases viz., autoimmune disorders, cancer, radiation injury, parkinsonism, alzheimer's disease, multiple sclerosis, myocardial infarction, atherosclerosis, diabetes, peptic ulcer, epilepsy, depression, nephrotoxicity, smoking induced respiratory disorders, etc. (Christensen and Somers, 1996; Halliwell and Gutteridge, 1999; Sharma and Sharma, 2008; Flerov and Shalyapina, 2009). Oxidative stress is caused by - Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS). ROS are either free radicals (superoxide anion radical $^1\text{O}_2^\bullet$, $^\bullet\text{OH}$) or non radicals that are oxidizing agents and/or easily convert into radicals (HOCl , HOBr , O_3 , ONOO^- , H_2O_2). Similarly RNS are either free radicals (NO^\bullet , NO_2^\bullet) or non radicals (HNO_2 , N_2O_4). These are capable of damaging nucleic acids, lipids, proteins and carbohydrates and also can cause DNA damage, cellular damage and neuronal death (Halliwell and Gutteridge, 1999; Gulcin *et al.*, 2003). Cells contain two types of natural defense systems-enzymes to detoxify (viz., superoxide dismutase, catalase and peroxidase) and antioxidants (vitamins C and E, glutathione, ferritin and uric acid). Saturation of these defense systems causes oxidative stress (Arzimanoglou *et al.*, 2002). The defense mechanisms act by removing oxygen or decreasing local oxygen concentration, removing catalytic metal ions, ROS and RNS, quenching or scavenging initiating free radicals, breaking the chain of initiated sequence, enhancing endogenous antioxidant defenses by up-regulating expression of genes encoding the antioxidant enzymes, repairing oxidative damage caused by radicals, increasing elimination of damaged molecules and not repairing excessively damaged molecules in order to minimize introduction of mutation (Wood *et al.*, 2006). Thus therapies aimed at reducing oxidative stress may ameliorate tissue damage and favorably alter the clinical course (Costello and Delanty, 2004; Anupama *et al.*, 2010).

In the present study we have taken up two *in vitro* antioxidant models-free radical scavenging activity and metal chelating activity, to test the antioxidant potential of IK.

MATERIALS AND METHODS

The present study was carried out during spring/summer, 2010 at Sultan-ul-Uloom College of Pharmacy, Hyderabad, India.

Drug: IK was obtained from M/s Hamdard (Wakf) Laboratories, Ghaziabad, Uttar Pradesh, India and was dissolved in methanol and filtered.

Chemicals: DPPH[•] (1,1-Diphenyl-2-picrylhydrazyl radical) was obtained from Sigma, New Delhi, India. L-Ascorbic Acid (AA), Ferrous Chloride (FeCl₂), ferrozine, disodium Ethylene Diamine Tetra Acetate (EDTA) and solvents were obtained from sd-fine Chemicals, Mumbai, India. All the chemicals were of analytical grade.

Free radical scavenging activity: The free radical scavenging activity of IK was measured employing the method of Blois (1958). To 1 mL of different concentrations (1, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 µg mL⁻¹) of IK, 1 mL of 0.1 mM solution of DPPH[•] in methanol was added and stirred vigorously on vortex mixer. The reaction mixture was kept in dark for 30 min and the absorbance was measured at 517 nm using UV-Spectrophotometer (Shimadzu, Japan). A control containing 1 mL water and standard containing different concentrations of AA (1-100 µg mL⁻¹) were prepared to which DPPH[•] was added as above. All measurements were made in triplicate and their means were taken. Percentage inhibition was calculated using the formula:

$$\text{Inhibition (\%)} = \frac{(A_o - A_s)}{A_o} \times 100$$

where, A_o and A_s are absorbencies of control and sample/standard respectively. IC₅₀ values introduced by Brand-Williams *et al.* (1995) were calculated using online software of TMDU Chemical Biology Database.

Metal chelating activity: The chelation of ferrous ions was estimated by method of Dinis *et al.* (1994). To the tubes containing 1.7 mL of deionized water, 50 µL of 0.2 mM FeCl₂·4H₂O and 50 µL of different concentrations of IK (20, 40, 60, 80 and 100 µg mL⁻¹) were added mixed and kept aside for 1 min. The reaction was initiated by the addition of 0.2 mL of 5 mM ferrozine, mixed on a vortex mixer and after 10 min the absorbance of the solutions were measured at 562 nm in a UV-Vis Spectrophotometer (Shimadzu, Japan). All tests and analyses were made in triplicates. The percentage of inhibition of ferrozine-Fe²⁺ complex formation was calculated as follows:

$$\text{Inhibition (\%)} = \frac{(A_o - A_s)}{A_o} \times 100$$

where, A_o and A_s are absorbencies of control and sample/standard respectively. IC₅₀ values introduced by Brand-Williams *et al.* (1995) were calculated using online software of TMDU Chemical Biology Database.

Statistical analysis: Results were presented as Mean±SD. Statistical analysis was performed using Graphpad instat software. The values p<0.05 were considered significant after performing Duncan's multiple range test.

RESULTS AND DISCUSSION

Free radical scavenging activity: The free radical scavenging activity of IK was evaluated through its ability to quench the DPPH• using ascorbic acid as reference. The results are shown in Table 1. IK showed free radical scavenging activity and the IC₅₀ values of IK and AA were found to be 25.14 and 21.23 µg mL⁻¹, respectively (Fig. 1).

Metal chelating activity: IK interfered with chelation of Fe²⁺ ions in a dose dependant manner reducing the intensity of the color of Fe²⁺-ferrozine complex. Results are shown in Table 2.

Table 1: DPPH• scavenging activity of Ascorbic Acid (AA) and Itrifal Kishneezi (IK)

Concentration (µg mL ⁻¹)	Inhibition of DPPH• radical (%)			
	AA		IK	
	Mean	±SD	Mean	±SD
0	0.0	0.0	0.0	0.0
1	8.8	9.2	4.8	3.2
10	24.1	4.7	15.6	5.3
20	49.1	5.6	34.3	5.9
30	64.9	1.7	61.1	4.8
40	86.1	0.5	84.4	4.7
50	95.6	0.2	93.3	2.2
60	95.7	0.1	95.2	2.1
70	96.9	0.2	96.2	2.2
80	97.2	0.2	95.9	1.1
90	97.2	0.1	96.9	0.9
100	97.3	0.2	98.8	0.9

p<0.05 Duncan's multiple range test




Fig. 1: IC₅₀ values of Itrifal Kishneezi in DPPH• scavenging and metal chelating activities


Table 2: Metal chelating activity of EDTA and Itrifal Kishneezi (IK)

Concentration ($\mu\text{g mL}^{-1}$)	Inhibition of metal chelation (%)			
	EDTA		IK	
	Mean	SD	Mean	SD
0	0.0	0.0	0.0	0.0
20	58.5	0.4	38.7	3.1
40	98.6	0.3	77.1	6.6
60	98.7	0.2	92.9	4.1
80	98.9	0.1	95.4	7.2
100	99.0	0.1	96.4	8.6


p<0.05 Duncan's multiple range test

Concentration for 50% inhibition of metal chelation (IC_{50}) by IK was found to be $24.08 \mu\text{g mL}^{-1}$ and that of disodium EDTA was $19.08 \mu\text{g mL}^{-1}$ (Fig. 1).

Studies indicate that the Reactive Oxygen Species (ROS) can induce epithelial dysfunction and macrophage activation resulting in the release of cytokines and growth factors that stimulate matrix remodeling and proliferation of smooth muscles. Oxidation processes are also involved in the cross linking of collagen fibers resulting in long term vascular constriction (Huq, 2007). DPPH^\bullet is considered to be a model of lipophilic radicals which initiate lipid auto oxidation (Dinis *et al.*, 1994). DPPH^\bullet is characterized as a stable free radical by virtue of delocalization of the spare electron over the molecule as a whole so that the molecules do not dimerize, as would be case with other free radicals. The delocalization also gives rise to deep violet color, characterized by an absorption band at 517 nm. When a solution of DPPH^\bullet is mixed with a substance that can donate hydrogen atom, it reduces to DPPHH (1,1-Diphenyl-2-picrylhydrazine, pale yellow color from the picryl group still present) (Molyneux, 2004).



Metal chelating activity (Brand-Williams *et al.*, 1995) is claimed as one of the antioxidant mechanisms, since it reduces the concentration of bivalent transition metal ions which act as catalysts in lipid peroxidation leading to formation of hydroxyl radicals and hydrogen peroxide decomposition reactions via fenton reactions (Halliwell, 1997). Ferrozine quantitatively forms complexes with Fe^{2+} , however in presence of chelating agents, the complex formation is disrupted and the dark red color (562 nm) of the complex decreases. The color reduction allows the estimation of chelating activity of co-existing chelator. IK quenched the DPPH^\bullet and interfered with chelation of Fe^{2+} ions in a dose dependant manner.



Ferroquine (3-(2-pyridyl)-5,6-bis(4-phenyl-sulfonic acid)-1,2,4-triazine)

There is no published research evidence available on the activity of Itrifal Kishneezi, though most of its ingredients are widely studied for antioxidant activity (Chattopadhyay and Bhattacharyya, 2007; Chithra and Leelamma, 1999; Sabu and Kuttan, 2009). Some of the ingredients of the present formulation are rich sources of tannins and flavonoids which are phenolic compounds and may be responsible for its antioxidant activity (Uddin *et al.*, 2008). The medicinal properties of plants have been centre of attraction for researchers in recent scientific developments throughout the world, due to their potent antioxidant properties, no side effects and economic viability (Gupta and Sharma, 2010). Unani medicines are formulated generally from natural resources and are well tolerated and this system of medicine needs to be deeply explored for the benefit of mankind.

CONCLUSIONS

Unani medicines are used extensively, but as they lack modern scientific evidence, they are not accepted by conventional medicine practitioners. Itrifal Kishneezi showed antioxidant activity by its free radical scavenging and metal chelating activities and also might reduce the free radical generation, quench the radicals already formed and inhibit neuronal and other free radical mediated damages. Further studies are required to determine its mechanism of action and *in vivo* studies.

ACKNOWLEDGMENT

The authors sincerely thank the management of Sultan-ul-Uloom College of Pharmacy, Hyderabad, Andhra Pradesh, India, for providing all the facilities for the present research.

REFERENCES

- Ahmad, B. and J. Akhtar, 2009. Unani system of medicine. *Phcog. Rev.*, 1: 210-213.
- Al-Said, M.S., K.I. Al-Khamis, M.W. Islam, N.S. Parmar, M. Tariq and A.M. Ageel, 1987. Post-coital antifertility activity of the seeds of *Coriandrum sativum* in rats. *J. Ethnopharmacol.*, 21: 165-173.
- Al-Waili, N.S., 2004. Investigating the antimicrobial activity of natural honey and its effects on the pathogenic bacterial infections of surgical wounds and conjunctiva. *J. Med. Food*, 73: 210-222.
- Anand, K.K., B. Singh, A.K. Saxena, B.K. Chandan, V.N. Gupta and V. Bhardwaj, 1997. 3, 4, 5-Trihydroxybenzoic acid (gallic acid), the hepatoprotective principle in the fruits of *Terminalia belerica* bioassay guided activity. *Pharmacol. Res.*, 36: 315-321.

- Anupama, K., S. Satyanarayana, K. Mukkanti and K.A. Khan, 2010. *In vitro* antioxidant activity of Hab-e-jund [unani medicine] prescribed for febrile convulsions. Pharmacologyonline, 1: 943-949.
- Anupama, K., S. Satyanarayana, K. Mukkanti, K.A. Khan and K.P. Kumar, 2009. Protective activity of Hab-e-jund a unani formulation against convulsions in mice. Pharmacologyonline, 3: 724-731.
- Arzimanoglou, A., E. Hirsch, A. Nehlig, P. Castelnaud, P. Gressens, A.P. de Vasconcelos, 2002. Epilepsy and neuroprotection: An illustrated review. Epileptic Disord., 4: 173-182.
- Bilsel, Y., D. Bugra, S. Yamaner, T. Bulut, U. Cevikbas and U. Turkoglu, 2002. Could honey have a place in colitis therapy? Effects of honey, prednisolone and disulfiram on inflammation, nitric oxide and free radical formation. Dig. Surg., 19: 306-312.
- Blois, M.S., 1958. Antioxidant determinations by the use of a stable free radical. Nature, 181: 1199-1200.
- Brand-Williams, W., M.E. Cuvelier and C. Berset, 1995. Use of free radical method to evaluate antioxidant activity. LWT Food Sci. Technol., 28: 25-30.
- Chattopadhyay, R.R. and S.K. Bhattacharyya, 2007. Plant review *Terminalia chebula*: An update. Pharmacog. Rev., 1: 151-156.
- Chithra, V. and S. Leelamma, 1997. Hypolipidemic effect of coriander seeds (*Coriandrum sativum*): Mechanism of action. Plant Foods Hum. Nutr., 51: 167-172.
- Chithra, V. and S. Leelamma, 1999. Coriandrum sativum changes the levels of peroxides and activity of antioxidant enzymes in experimental animals. Indian J. Biochem. Biophys., 36: 59-61.
- Christensen, L. and S. Somers, 1996. Comparison of nutrient intake among depressed and non depressed individuals. Int. J. Eat. Dis., 20: 105-109.
- Costello, D.J. and N. Delanty, 2004. Oxidative injury in epilepsy: Potential for antioxidant therapy? Expert Rev. Neurother., 46: 541-553.
- Dinis, T.C., V.M. Maderia and L.M. Almeida, 1994. Action of phenolic derivatives (acetaminophen, salicylate and 5-aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers. Arch. Biochem. Biophys., 315: 161-169.
- Dwivedi, S., A. Dwivedi, R. Kapadia and S. Kaul, 2008. Anthelmintic Activity of alcoholic and aqueous extract of fruits of *Terminalia chebula* Retz. Ethnobot. Leaflets, 12: 741-743.
- Evans, W.C., 2006. Trease and Evans Pharmacognosy. 15th Edn., Elsevier, New Delhi, India.
- Flerov, M.A. and V.G. Shalyapina, 2009. Free-radical lipid oxidation in the brains of active and passive rats during the development of post-stress depression. Neurosc. Behav. Phys., 39: 471-474.
- Gray, A.M. and P.R. Flatt, 1999. Insulin-releasing and insulin-like activity of the traditional anti-diabetic plant *Coriandrum sativum* (coriander). Brit. J. Nutr., 81: 203-209.
- Gulcin, I., M. Oktay, E. Kirecci and O.I. Kufrevioglu, 2003. Screening of antioxidant and antimicrobial activities of anise (*Pimpinella anisum* L.) seed extracts. Food Chem., 83: 371-382.
- Gupta, A.K., 2003. Handbook on Unani Medicine with Formulae, Processes, Uses and Analysis. Asia Pacific Business Press Inc., Delhi, India.
- Gupta, V.K. and S.K. Sharma, 2010. *In vitro* antioxidant activities of aqueous extract of *Ficus bangalensis* Linn. Root. Int. J. Biol. Chem., 4: 134-140.
- Halliwell, B. and J.M.C. Gutteridge, 1999. Free Radicals in Biology and Medicine. 1st Edn. Oxford University Press, New York.

- Halliwell, B., 1997. Antioxidants: The basics--what they are and how to evaluate them. *Adv. Pharmacol.*, 38: 3-20.
- Huq, F., 2007. Molecular modelling analysis of the antioxidant activity of probucol. *Asian J. Biochem.*, 2: 354-358.
- Inamdar, M.C., M.L. Khorana and M.R.R. Rao, 1959. Antibacterial and antifungal activity of *Terminalia chebula* Retz. *Indian J. Pharm.*, 21: 333-335.
- Jadon, A., M. Bhadauria and S. Shukla, 2007. Protective effect of *Terminalia belerica* Roxb. and gallic acid against carbon tetrachloride induced damage in albino rats. *J. Ethnopharm.*, 109: 214-218.
- Kabeeruddin, M., 1989. Biyaz-e-Kabeer. Hikmat Book Depot, Hyderabad, India.
- Kaur, S., I.S. Grover, M. Singh and S. Kaur, 1998. Antimutagenicity of hydrolysable tannins from *Terminalia chebula* in *Salmonella typhimurium*. *Mut. Res.*, 419: 169-179.
- Khanna, A.K., R. Chander, N.K. Kapoor, C. Singh and A.K. Srivastava, 1993. Hypolipidemic activity of *Terminalia chebula* in rats. *Fitoterapia*, 64: 351-356.
- Khare, C.P., 2007. *Indian Medicinal Plants: An Illustrated Review*. Springer-Verlag, USA.
- Kokate, C.K., A.P. Purohit and S.B. Gokhale, 2002. *Pharmacognosy*. 18th Edn., Nirali Prakashan, Pune, India.
- Madani, A. and S.K. Jain, 2008. Anti-Salmonella activity of *Terminalia belerica*: *In vitro* and *in vivo* studies. *Indian J. Exp. Biol.*, 46: 817-821.
- Medhin, D.G., P. Hadhazy, P. Bakos and G. Verzar-Petri, 1986. Hypotensive effects of *Lupinus termis* and *Coriandrum sativum* in anesthetized rats. A preliminary study. *Acta Pharma. Hung.*, 56: 59-63.
- Miglani, B.D., P. Sen and R.K. Sanyal, 1971. Purgative action of an oil obtained from *Terminalia chebula*. *Indian J. Med. Res.*, 59: 281-283.
- Molan, P.C., 2006. The evidence supporting the use of honey as a wound dressing. *Int. J. Lower Extremity Wounds*, 5: 40-54.
- Molyneux, P., 2004. The use of the stable free radical diphenylpicrylhydrazyl (DPPH) for estimating antioxidant activity. *Songklanakarin J. Sci. Technol.*, 26: 211-219.
- Rehman, Z.H., 1985. *Kitabul Murakhbat*. 1st Edn., Aligarh Muslim University, Madhya Pradesh, India.
- Sabu, M.C. and R. Kuttan, 2009. Antidiabetic and antioxidant activity of *Terminalia belerica* Roxb. *Indian J. Exp. Biol.*, 47: 270-275.
- Saleem, A., M. Husheem, P. Harkonen and K. Pihlaja, 2002. Inhibition of cancer cell growth by crude extracts and the phenolics of *Terminalia chebula* retz. fruit. *J. Ethnopharm.*, 81: 327-336.
- Sharma, H.L. and K.K. Sharma, 2008. *Principles of Pharmacology*. Paras Medical Publisher, Hyderabad, India.
- Shastri, A.D., 1998. *Shushrut Samhita*. 11th Edn., Chaukhamba Sanskrit Prakashan, Varanasi, India.
- Swanston-Flatt, S.K., C. Day, C.J. Bailey and P.R. Flatt, 1990. Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. *Diabetologia*, 33: 462-464.
- Uddin, S.N., M.E. Ali and M.N. Yesmin, 2008. Antioxidant and antibacterial activities of *Senna tora* roxb. *Am. J. Plant Physiol.*, 3: 96-100.
- Wood, L.G., P.G. Gibson and M.L. Garg, 2006. A review of the methodology for assessing *in vivo* antioxidant capacity. *J. Sci. Food Agri.*, 86: 2057-2066.